JPRN-jRCT1080223795已完成Unknown
TRIBIK Drug Use Surveillance
The Research Foundation for Microbial Diseases of Osaka University0 个研究点目标入组 921 人开始时间: 2018年2月2日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 921
研究概览
简要总结
The incidence of adverse reactions in 869 subjects included in the safety analysis was 55.35%, and no significant adverse reactions were reported. There were no occurrence of shock, anaphylaxis, or vasovagal syncope. The results of this surveillance did not identify any new safety concern to be included in the RMP.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 90month old 至 ot applicable（—）
- 性别
- All
入选标准
- •Vaccinees who meet both of the following conditions [1] and [2]:
- •[1] Vaccinees who received TRIBIK at the age of 90 months and over.
- •[2] Vaccinees who are able to participate in a questionnaire survey on the health status after vaccination with TRIBIK ( or vaccinees whose guardians are able to participate in the questionnaire survey).
排除标准
- 未提供
研究者
相似试验
已完成
不适用
KADCYLA drug use surveillanceBreast cancerJPRN-UMIN000017702Chugai Pharmaceutical Co., Ltd.250
已完成
不适用
Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis BJPRN-UMIN000008045Chugai Pharmaceutical Co., Ltd.536
已完成
4 期
A postmarketing all-case surveillance of mogamulizumab in patients with CCR4 positive relapsed or refractory adult T cell lymphoma-leukemiaCCR4-positive relapsed or refractory adult T cell leukemia-lymphomaJPRN-UMIN000025368Kyowa Kirin Co., Ltd.597
已完成
不适用
General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphomaRelapsed or refractory diffuse large B-cell lymphomaJPRN-UMIN000043840Chugai Pharmaceutical Co. Ltd.1,877
已完成
不适用
Stamaril ResearchYellow feverJPRN-jRCTs031180027Ohmagari Norio11,287